Positive results from BIOFLOW-II clinical trial

Article

Primary endpoint results, demonstrating the non-inferiority of the BIOTRONIK Orsiro hybrid drug-eluting stent compared to Abbott?s XIENCE PRIME, from the BIOFLOW-II clinical study have been revealed at the EuroPCR congress in Paris.

Primary endpoint results, demonstrating the non-inferiority of the BIOTRONIK Orsiro hybrid drug-eluting stent compared to Abbott's XIENCE PRIME, from the BIOFLOW-II clinical study have been revealed at the EuroPCR congress in Paris.

The results were presented by Dr Stephan Windecker (University of Bern, Switzerland) and showed that the Orsiro met the primary endpoint of in-stent late lumen loss at 9 months, which equals that of the XIENCE PRIME. "The Orsiro stent met the primary non-inferiority endpoint of late loss at 9 months compared to the XIENCE PRIME stent, demonstrating effectiveness of drug elution from this bioabsorbable polymer," said Dr Windecker. "The platform also appears to be safe, with low rates of myocardial infarction and revascularization and no reported stent thrombosis."

In addition to these results, the primary endpoint results from the BIOFLOW-III registry were also presented by Professor Johannes Waltenberger (Universitätsklinikum Münster, Germany). The 12 month BIOFLOW-III results demonstrated the safety and efficacy of the stent in a larger and more complex patient population, according to Prof. Waltenberger.

Further information may be found here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.